Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Medtronic

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - CVS Health (NYSE:CVS), Amgen (NASDAQ:AMGN)

Walgreens

The U.S. Food and Drug Administration (FDA) announced Tuesday that it has sent warning letters to eight companies the agency said are violating federal by manufacturing or marketing unapproved eye treatment products.

CVS, Walgreens Get FDA Warning for Selling Unapproved Eye Drops

CVS Health Corporation (NYSE:CVS ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 12, 2023 8:50 AM ET Company Participants Karen Lynch - President, Chief Executive Officer Shawn Guertin - Executive Vice President, Chief Financial Officer Larry McGrath - Senior Vice President, Investor Relations Conference Call Participants Erin Wright - Morgan Stanley Erin Wright Hi. Good morning, everyone.

CVS Health Corporation (CVS) CEO Karen Lynch Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)

The U.S. Food and Drug Administration this week warned CVS Health Corp. CVS, +2.78%, Walgreens Boots Alliance Inc. WBA, +3.17% and several smaller consumer products companies about marketing unapproved eye products. “The FDA is particularly concerned that these illegally marketed, unapproved ophthalmic drug products pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body's natural defenses,” the FDA said in a release Tuesday.

FDA warns CVS, Walgreens about marketing of unapproved eye products

The U.S. Food and Drug Administration on Tuesday said it has issued warning letters to eight companies, including pharmacy giants CVS Health Corp and Walgreens Boots Alliance , for manufacturing or marketing unapproved ophthalmic drug products.

FDA issues warning letter to CVS, Walgreens and others for selling unapproved eye products

Apple

Bank of America

Disney

Alphabet

JPMorgan Chase & Co

Morgan Stanley

Microsoft

Pfizer

Seasonal tendencies for the U.S. stock market between now and the end of the year will favor large-cap stocks over small caps.

Why large-cap stocks are a better bet for the rest of 2023 — and 10 you want to own

Archer-Daniels-Midland Company

Dow Inc

Energy Transfer LP Unit

Ford Motor Company

ManpowerGroup

Omnicom Group

Philip Morris

Southern Company

Sysco

Verizon

A Summer 2023 edition of Fortune Magazine revealed 500 biggest U.S. companies by revenue. The quest to sniff-out the best dividend buys focused on 68 industry leaders using YCharts 9/7/23. Those 68 industry leaders were segmented into 21 business sectors ranging (alphabetically) from apparel to transportation. 58 dividend yielding stocks highlighted those 68 industry leaders and ranged 0.15% to 9.05% in annual yield and ranged -65.47% to 45.11% in broker-estimated one-year price-target-upsides by YCharts 9/7/23 reckoning.

4 Ideal Fortune 500 Top September Dividend Dogs

CVS Health shook up its executive suite, adding responsibilities for several members of the company's executive leadership team.

CVS Health Shuffles C-Suite Responsibilities, Adds New Roles And New Hires

WOONSOCKET, R.I. , Sept. 7, 2023 /PRNewswire/ -- CVS Health® Corporation (NYSE: CVS) today announced additional responsibilities for several members of the company's executive leadership team, effective immediately: Shawn Guertin will continue as our Chief Financial Officer and is now President of Health Services.

CVS Health announces additional responsibilities for executive leadership team members

CVS Group (AIM:CVSG) and Pets at Home Group PLC (LSE:PETS) plunged on Thursday after the UK's competition agency launched an investigation to find out whether customers are being given the best deal when it comes to caring for their four-legged friends. Members of the public have welcomed the review, with some pet owners taking to X to express their desire for the industry reform.

Pet owners welcome vet probe as CVS and Pets at Home plummet

CVS Health stock (NYSE: CVS) currently trades at $66 per share, about 12% lower than the level seen in March 2021, and it can see higher levels over time.

Will CVS Health Stock Recover To Its Pre-Inflation Shock Highs Of $110?

AbbVie

Citigroup

Caterpillar

Citizens & Northern

General Dynamics

Kinder Morgan

National Grid

Norfolk Southern

Norwood Financial

Realty Income Corp

Healthpeak Properties

Premier Financial

Provident Financial Services

Procter & Gamble

Starbucks

AT&T

Texas Instruments

WestRock

We invest in dividend stocks to grow passive income and eventually cover monthly expenses for early retirement. We use a stock screener to find undervalued stocks with a strong payout ratio and a history of increasing dividends. In August, we received $1,097 in dividend income, with notable contributions from National Grid and Texas Instruments.

Bert's August 2023 Dividend Income Summary

CVS Pharmacy® and MinuteClinic® encourage consumers to get an annual flu shot and stay up to date on routine vaccinations Schedule ahead available for flu and RSV vaccinations, allowing patients to plan ahead and secure a convenient appointment WOONSOCKET, R.I. , Sept. 6, 2023 /PRNewswire/ -- CVS Health ®  (NYSE: CVS) is prepared to meet patients' vaccination and other preventive health care needs as flu season approaches.

CVS Health survey finds more than two-thirds of Americans plan to get a flu shot this season

Charter Communications

Cigna

Expedia

Generac Holdings

Renowned investor Michael Burry, famous for his astute predictions, has garnered attention in the past due to his stock positions. Despite this interest, the ‘Big Short' investor has, in recent months, expressed a bearish position in the general stock market at some point advising investors to ‘sell'.

‘Big Short' Michael Burry's top 5 portfolio positions

Deere & Company

Illinois Tool Works

Orrstown Financial

Essential Utilities

2023 has been one heck of a year. The S&P 500 is close to all-time highs. The Fed raised interest rates in July, as the economy is still on fire. The retirement accounts brought in a total dividend income amount of $379.48 or 22% of the dividend income total, similar to last month. Dividend increases created $42.95 in additional passive dividend income.

Dividend Income Summary: Lanny's August 2023 Summary

Shares of Medtronic and CVS Health offer above-average dividend yields after falling significantly in recent weeks. One of CVS Health's integrated healthcare businesses recently experienced a setback, but its overall future still looks bright.

2 Underappreciated Dividend Stocks to Buy in September and Hold Forever

CVS is going to commercialize a biosimilar to Humira. Humira probably won't be the last high-earning drug it copies.

Could CVS Make a Copy of Ozempic?

Viatris

CVS Health is getting into the biosimilar drug business that Viatris just exited. CVS could potentially target other types of generic medicines next.

CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know

CVS will soon commercialize biosimilar medicines, starting with Humira. The move will likely drive a faster pace of growth, but not by a huge amount.

CVS Just Made a Major New Announcement, But Should You Buy It?

WOONSOCKET, R.I. , Aug. 31, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that President and CEO Karen S.

CVS Health to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

WOONSOCKET, R.I. , Aug. 29, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) is actively preparing for Hurricane Idalia's impending landfall along Florida's Gulf Coast.

CVS Health supporting customers, patients, members and colleagues as Hurricane Idalia approaches

News for CVS Health Stock (CVS)